NCT07788131Not yet recruiting
Inflammatory Biomarkers and Disease Activity in Inflammatory Bowel Disease
Evaluation of Inflammatory Biomarkers for Disease Activity in Patients With Inflammatory Bowel Disease
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
This study aims to evaluate the diagnostic accuracy and clinical utility of routine blood-derived inflammatory biomarker ratios in assessing disease activity among adult patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Endoscopy is the standard method for evaluating mucosal inflammation in IBD, but it is invasive, costly, and inconvenient for frequent disease monitoring. Non-invasive, inexpensive laboratory markers derived from standard routine blood tests, specifically the C-reactive protein-to-albumin ratio (CAR), platelet-to-albumin ratio (PAR), neutrophil-to-lymphocyte ratio (NLR), fibrinogen-to-albumin ratio (FAR), and hemoglobin-to-CRP ratio (Hb/CRP), have shown potential in reflecting systemic and intestinal inflammation. Participants enrolled in this cross-sectional study will undergo routine clinical disease activity evaluations and standard blood tests. For patients undergoing routine colonoscopy, endoscopic disease activity scores will also be recorded. The primary goal is to determine how accurately these blood-based ratios can differentiate active IBD from disease remission, providing a simple, cost-effective tool for regular patient monitoring.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 22 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT07788131
What you commit to
- Study type: Observational
- Planned participants: 120
- From Sept 2026 to the primary completion date, Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent major surgery
Other illness
- Acute systemic infection at the time of assessment
- Active malignancy
- Other active systemic inflammatory or autoimmune diseases likely to significantly influence inflammatory biomarkers
Lab values
- Significant hematological disease affecting hemoglobin, leukocyte, neutrophil, lymphocyte, or platelet counts
- Severe renal or hepatic dysfunction likely to substantially influence albumin or inflammatory markers
Other
- Pregnancy
Who the study is looking for
- Age 18 years or older
- Established diagnosis of Crohn's disease or ulcerative colitis
- Availability of adequate clinical information for disease activity assessment
- For the endoscopic subgroup: colonoscopy performed as part of routine clinical care within the study window with an available endoscopic report and corresponding disease activity score
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.